Calcific aortic stenosis (CAVS) is the most common form of valvular heart disease in developed countries, increasing in prevalence with the aging population. Surgical or transcatheter aortic valve replacement is the only treatment available for CAVS. However, these interventions are typically reserved for severe symptomatic aortic stenosis (AS). The purpose of this review is to summarize the recent literature in uncovering the underlying pathophysiology of CAVS in the setting of lipoprotein (a) [Lp(a)] and emerging therapies targeting Lp(a) which may help halt disease progression in CAVS.

中文翻译：

---

钙化性主动脉瓣疾病中脂蛋白（a）的现状。

钙化性主动脉瓣狭窄 (CAVS) 是发达国家最常见的瓣膜性心脏病，随着人口老龄化而患病率增加。手术或经导管主动脉瓣置换是 CAVS 唯一可用的治疗方法。然而，这些干预措施通常用于严重的症状性主动脉瓣狭窄 (AS)。这篇综述的目的是总结最近的文献，以揭示脂蛋白（a）[Lp（a）] 中 CAVS 的潜在病理生理学，以及针对 Lp（a）的新兴疗法，这可能有助于阻止 CAVS 的疾病进展。